Avient (AVNT) Q2 2025 earnings summary

Executive summary

• Achieved fifth consecutive quarter of organic revenue growth, with Q2 2025 sales up 2% year-over-year to $866.5M, including a 1% favorable FX impact, and strong demand in defense and healthcare offsetting weak consumer markets.

• Adjusted EPS grew 5% to $0.80, slightly above guidance, with adjusted EBITDA margin expanding to 17.2%; GAAP EPS was $0.57, up from $0.36.

• Net income attributable to shareholders was $52.6M, up from $33.6M, with operating income increasing to $96.1M.

• Strong cash flow from operations ($113M in Q2) enabled $50M in debt repayment, supporting ongoing deleveraging and liquidity.

• Patent filings up 50% in 2024, with further increases expected in 2025, reflecting innovation focus.

Financial highlights

• Q2 2025 sales reached $866.5M (+2.0% YoY); adjusted EBITDA for Q2 was $149M, up 3.9% as reported, with a margin of 17.2% (up 30bps YoY).

• Adjusted EPS for Q2 was $0.80, a 5.3% increase as reported and slightly ahead of guidance.

• H1 2025 sales: $1.69B (+0.9% YoY); adjusted EBITDA margin expanded 20bps to 17.3%.

• Free cash flow for FY 2025 expected between $190M and $210M; CapEx guidance at $110M.

• Paid down $50M in debt in Q2; on track to reduce debt by $100M–$200M by year-end.

Outlook and guidance

• Full-year 2025 adjusted EBITDA guidance narrowed to $545M–$560M, representing 4%–6% growth excluding FX; adjusted EPS guidance set at $2.77–$2.87.

• Q3 2025 adjusted EPS expected at $0.70, up 8% year-over-year, driven by higher margins.

• Demand environment for H2 expected to mirror H1, with low single-digit revenue change scenarios.

• Raw material inflation expected at 1%–2% for the year.

• Management expects sufficient liquidity for at least the next twelve months, with cash, operations, and revolving credit as primary sources.